The following errors were in the Quarterly Earnings Reports chart in the Oct. 29, 2001, issue of BioWorld Today:
¿ Bio-Technology General¿s net income for the third quarter of 2001 and 2000 was reported correctly, but its per-share amounts were not. Bio-Technology General posted per-share earnings of 6 cents for 2001¿s third quarter and 8 cents for the same period in 2000.
¿ The figures for Ciphergen Biosystems Inc. transposed results for the third quarter 2000 and 2001. Correct figures follow: Total revenues were $5,404,000, an increase of 131 percent. It posted a net loss of $6,916,000 for 2001¿s third quarter and $6,171,000 in same period last year. Its loss per share was 26 cents for the period, and 89 cents for the third quarter of 2000. It spent $3,264,000 on R&D, a 64 percent increase over 2000¿s third quarter. It had cash and cash equivalents of $81,628,000 as of Sept. 30, and computed its loss per share on 26,593,000 shares.
Editor¿s Note: The corrections have been made in BioWorld Online.